R&D Insights: How Pfizer Inc. and TG Therapeutics, Inc. Allocate Funds

R&D Spending: A Tale of Two Companies

In the ever-evolving pharmaceutical landscape, research and development (R&D) spending is a critical indicator of innovation and future growth. Pfizer Inc., a global pharmaceutical giant, and TG Therapeutics, Inc., a burgeoning biotech firm, offer a fascinating contrast in their R&D allocations over the past decade.

From 2014 to 2023, Pfizer's R&D expenses surged by approximately 27%, peaking in 2021 with a remarkable 14% increase from the previous year. This reflects Pfizer's commitment to maintaining its leadership in drug development, especially during the COVID-19 pandemic.

Conversely, TG Therapeutics, while smaller in scale, demonstrated a consistent upward trend in R&D investment, with a notable 533% increase from 2014 to 2021. This underscores the company's aggressive pursuit of innovative therapies in the oncology and autoimmune sectors.

These insights reveal the strategic priorities of both companies, highlighting the diverse approaches to innovation in the pharmaceutical industry.